


The bright future of mRNA technology - InConversation

Podcast #Episode1: w/Thomas D. Madden, Founder, Acuitas Therapeutics



23.02.2021

Tags: [Global](#), [Canada](#), [Vaccines](#), [Acuitas](#), [Pfizer](#), [BioNTech](#), [Coronavirus](#), [mRNA](#), [Podcast](#)

Dr Thomas D. Madden, CEO and founder of Acuitas Therapeutics, shares the story behind their involvement in Pfizer and BioNTech's COVID-19 vaccine, the numerous applications of the company's proprietary lipid nanoparticle (LNP) delivery technology, as well as the growth strategy of the Canadian company.

pharmaboardroom · The bright future of mRNA technology w/Acuitas Therapeutics

[See more interviews](#)